COMP <GO>
NVCR vs TNDM // PIOTROSKI F-SCORE QUALITY
NovoCure Limited (NASDAQ) VS. Tandem Diabetes Care Inc. (NASDAQ) • 15-METRIC TALLY: NVCR 6
— TNDM 4
▲ PIOTROSKI F-SCORE QUALITY LEADER: NVCR
LAST: $13.15 (+0.31%) • MKT CAP: $1.53B
piotroski-score
6/9
LAST: $19.11 (-3.44%) • MKT CAP: $1.38B
piotroski-score
4/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVCR VS. TNDM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVCR | TNDM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | 53.80% | +20.70 | NVCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.50% | -35.00% | +7.50 | NVCR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.96% | -2.15% | -2.81 | TNDM | /fcf-yield <GO> |
| Operating Margin | -23.50% | -18.50% | -5.00 | TNDM | /operating-margins <GO> |
| Net Profit Margin | -20.80% | -20.20% | -0.60 | TNDM | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 7.90% | +0.40 | NVCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.54 | 0.20 | +0.34 | NVCR | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 4/9 | +2.00 | NVCR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.8 | 66.3 | -32.50 | TNDM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.53B | $1.38B | $149.6M | NVCR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVCR REV | TNDM REV | NVCR GROSS % | TNDM GROSS % | NVCR FCF | TNDM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $655.4M | $1.01B | 74.5% | 53.8% | -$75.7M | -$29.7M |
| FY 2024 | $605.2M | $940.2M | 77.3% | 52.1% | -$69.2M | $5.0M |
| FY 2023 | $509.3M | $747.7M | — | — | -$73.3M | -$31.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVCR // BETA —
TNDM // BETA —